Diagnostics is one of Indian healthcare's fastest-compounding businesses — and one of its most credential-driven. A pathology lab's licence stack is modest; its credibility stack (who signs reports, NABL accreditation) is everything, deciding which doctors refer, which insurers empanel and which corporate contracts arrive. Here is the full setup map: the mandatory registrations, the personnel rules that define legality, and the NABL path that defines growth.
The mandatory base stack
- Clinical establishment registration (or the state-Act equivalent) for the lab as a diagnostic establishment — provisional then permanent against lab minimum standards
- Biomedical waste authorisation + contract with a common treatment facility; segregation and manifest records
- Shops & Establishment registration; trade licence per municipality; GST as applicable (diagnostic services carry their own GST treatment — largely exempt as healthcare, watch the boundaries)
- Fire and building compliances per premises; PNDT only if imaging/ultrasound coexists
- For labs with X-ray/CT arms: AERB via eLORA
None of this is exotic; a focused six-to-eight weeks assembles it. The harder questions are people and quality.
Who may run and sign: the personnel core
The defining regulatory line in Indian pathology: reports must be signed by qualified persons — pathologists (MD/DNB Path) for histopathology/cytology and as laboratory directors; the space for MSc/PhD biochemists and microbiologists signing within their disciplines exists per NMC/court rulings and NABL norms but is bounded. Labs running on borrowed signatures ('ghost pathologists' lending names across dozens of labs) sit on legal quicksand — courts and councils have treated it as misconduct, and NABL assessments verify presence and workload plausibility. Structure genuine engagement: employed or visiting pathologists with defined hours, discipline-wise signatories documented, and technicians (DMLT/BMLT) under their supervision.
NABL: the growth credential
- NABL accreditation (ISO 15189 for medical labs) is voluntary in law, mandatory in practice for scale: insurer and TPA empanelment, corporate/government contracts and quick-commerce diagnostic tie-ins all ask for it
- Scope-wise: you accredit specific tests/disciplines; start with your volume tests
- The build: quality manual and SOPs, internal quality control (daily Levey-Jennings discipline), external quality assurance (EQAS enrolment — CMC/AIIMS programmes), method validation, calibration traceability, competency records
- Process: application → document review → pre-assessment (optional) → assessment → corrective actions → grant; typically 6–12 months from a standing start
- Entry-level schemes (NABL M(EL)T for basic labs) offer a stepped path for small labs
A small lab reaches NABL with roughly: consultant/documentation support, EQAS subscriptions, calibrations, and assessment fees — commonly a few lakhs all-in over the first cycle, plus the discipline. The empanelment revenue it unlocks typically repays this within quarters. Budget it as market access, not as compliance.
Collection centres and the franchise layer
Growth in diagnostics is a hub-and-spoke game: collection centres feeding a processing lab. Regulatory posture: centres operate under the mother lab's quality system (NABL norms govern collection-centre listing under the accredited lab), with trained phlebotomists, transport validation (time/temperature for samples), and local registrations (S&E, trade licence, BMW linkage through the hub's chain). Franchise agreements should hard-code sample-handling SOPs, branding-versus-signatory clarity (reports issue from the accredited lab), and audit rights — because every spoke's shortcut lands on the hub's accreditation.
How Aidwish helps
Aidwish builds diagnostic ventures end to end — the licence stack, signatory structuring, NABL documentation and assessment readiness, and collection-centre franchise kits — so labs earn the referrals their reports deserve.